UCB SA (EBR:UCB)
Belgium flag Belgium · Delayed Price · Currency is EUR
174.85
+0.85 (0.49%)
Jul 18, 2025, 5:39 PM CET

UCB SA Company Description

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.

The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome.

It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis.

Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; UCB0222 for the treatment of Parkinson’s disease; and UCB9741 and UCB1381 for atopic dermatitis.

Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

UCB SA
UCB SA logo
CountryBelgium
Founded1925
IndustryBiotechnology
SectorHealthcare
Employees9,378
CEOJean-Christophe Tellier

Contact Details

Address:
Allée de la Recherche, 60
Brussels, 1070
Belgium
Phone32 2 559 99 99
Websiteucb.com

Stock Details

Ticker SymbolUCB
ExchangeEuronext Brussels
Fiscal YearJanuary - December
Reporting CurrencyEUR
ISIN NumberBE0003739530
SIC Code2836

Key Executives

NamePosition
Dr. Jean-Christophe TellierChief Executive Officer and Executive Director
Sandrine Dufour CFAExecutive Vice President, Chief Financial Officer and Chief Corporate Development
Denelle J. Waynick Johnson J.D.Executive Vice President and General Counsel
Jean-Luc FleurialExecutive Vice President and Chief Human Resources Officer
Emmanuel CaeymaexExecutive Vice President and Chief Commercial Officer
Dr. Kirsten Lund-Jurgensen Ph.D.Executive Vice President of Patient Supply
Fiona du MonceauExecutive Vice President of Patient Evidence
Caroline VancoillieChief Accounting Officer, Head of Group Finance and Chief Financial Officer of Patient Value Functions
Alistair HenryExecutive Vice President and Chief Scientific Officer
Antje WitteHead of Investor Relations